Intellectual Property Newsletter by MeritsIP, September 07, 2026
# China's Recent IP Law Enforcement and Judicial Updates: Key Progress in Cross-Border Protection, Digital IP and Right Remedy # UK IPO Updates 2024 Examination Guidelines
- Welcome to MeritsIP Website -
- Home -Category: News ( Page 4 )
From Purinergic Inflammation Biology to an Oral IBD Medicine: The Global P2Y14 Receptor Antagonist Landscape
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Watch, a MeritsIP publication examining how emerging life science programs can translate into
From Dual Targeting to Multi-Mechanism Tumor Control: The Global Bispecific and Dual-Payload ADC Landscape
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Watch, a MeritsIP publication examining how emerging life science programs can translate into
From Reactive Toxicity Management to Built-In Cytokine Control: The Global Safety-Engineered CD19 CAR-T Landscape
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Watch, a MeritsIP publication examining how emerging life science programs can translate into
From Broad Immunomodulation to a Reproducible Cell Medicine: The Global Off-the-Shelf UC-MSC Therapeutics Landscape
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Watch, a MeritsIP publication examining how emerging life science programs can translate into
Intellectual Property Newsletter by MeritsIP, September 01, 2026
· Jiangsu: 81 Projects Win China Patent Awards · Beijing: 104 Invention Patents Win 26th China Patent Award · Second Session of the 26th China Patent
From Precision Editing to a Single-Course Cardiometabolic Medicine: The Global In-Vivo Base Editing Landscape
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Insight, a MeritsIP publication examining how emerging life science programs can translate into
Key points and strategic recommendations for patent layout in the cell therapy field
The successful launch of CAR-T drugs has made cell therapy a hotspot in biopharmaceutical research and development, sparking a global wave of patent deployment. Faced with
A CCR8 antibody and an ITGB6 ADC: A breakdown of BD value from mechanism to clinical practice
CCR8-targeted Treg clearing + ITGB6-targeted ADC,—— two differentiatedpipelines in a single biotech core judgment: This asset portfolio includes two independent and complementary pipelines: one CCR8-targeted ADCC
License-in and License-out: The two core logics for biopharmaceutical BD transactions
License-in and License-out are the two core models in biopharmaceutical BD transactions—the former buys equity with money, while the latter sells equity for money. Behind this lies